References
1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros
M, Znaor A, Bray F. Estimating the global cancer incidence and mortality
in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr
15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6. PMID:
30350310.
2. Li J, Siegel DA, King JB. Stage-specific incidence rates and trends
of prostate cancer by age, race, and ethnicity, United States,
2004-2014. Ann Epidemiol. 2018 May;28(5):328-330. doi:
10.1016/j.annepidem.2018.03.001. Epub 2018 Mar 6. PMID: 29678312; PMCID:
PMC6080305.
3. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M,
Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB,
Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van
der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening,
Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017
Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
PMID: 27568654.
4. Immediate versus deferred treatment for advanced prostatic cancer:
initial results of the Medical Research Council Trial. The Medical
Research Council Prostate Cancer Working Party Investigators Group. Br J
Urol. 1997 Feb;79(2):235-46. doi: 10.1046/j.1464-410x.1997.d01-6840.x.
PMID: 9052476.
5. Holzbeierlein JM, Castle E, Thrasher JB. Complications of androgen
deprivation therapy: prevention and treatment. Oncology (Williston
Park). 2004 Mar;18(3):303-9; discussion 310, 315, 319-21. PMID:
15065701.
6. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and
cardiovascular disease during androgen deprivation therapy:
observational study of veterans with prostate cancer. J Natl Cancer
Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec
7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. PMID:
19996060; PMCID: PMC3107568.
7. Marzouk S, Naglie G, Tomlinson G, Duff Canning S, Breunis H,
Timilshina N, Alibhai SMH. Impact of Androgen Deprivation Therapy on
Self-Reported Cognitive Function in Men with Prostate Cancer. J Urol.
2018 Aug;200(2):327-334. doi: 10.1016/j.juro.2018.02.073. Epub 2018 Mar
1. PMID: 29477720.
8. McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, Small
BJ, Jacobsen PB. Cognitive functioning in men receiving androgen
deprivation therapy for prostate cancer: a systematic review and
meta-analysis. Support Care Cancer. 2014 Aug;22(8):2271-80. doi:
10.1007/s00520-014-2285-1. Epub 2014 May 25. PMID: 24859915; PMCID:
PMC4090762.
9. Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, Ahern DK,
Kibel AS, Choueiri TK, Trinh QD. Cognitive Impairment in Men with
Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic
Review and Meta-Analysis. J Urol. 2018 Jun;199(6):1417-1425. doi:
10.1016/j.juro.2017.11.136. Epub 2018 Feb 2. PMID: 29410294.
10. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict
RH. Screening for cognitive impairment in multiple sclerosis using the
Symbol digit Modalities Test. Mult Scler. 2007 Jan;13(1):52-7. doi:
10.1177/1352458506070750. PMID: 17294611.
11. Benedict RH, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S,
Hamalainen P, Hartung H, Krupp L, Penner I, Reder AT, Langdon D. Brief
International Cognitive Assessment for MS (BICAMS): international
standards for validation. BMC Neurol. 2012 Jul 16;12:55. doi:
10.1186/1471-2377-12-55. PMID: 22799620; PMCID: PMC3607849.
12. Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological
tests. Administration, norms and commentary.3th ed. New York: Oxford
University Press; 2006.
13. Partington JE, Leiter RG. Partington’s Pathway Test. Psychological
Service Center Bulletin 1949;168:111-117.
14. Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the
Beck depression inventory-II. San Antonio, TX: Psychological
Corporation.
15. Cangoz B, Karakoc E, Selekler K. Standardization study of “Trail
Making Test” for Turkish adults and elderly people (ages 50 and over).
Turkish Journal of Geriatrics 2007; 10 (2): 73-82.
16. Alibhai SM, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock
I, Naglie G, Tomlinson G, Fleshner N, Krahn M, Warde P, Canning SD.
Impact of androgendeprivation therapy on cognitive function in men with
nonmetastatic prostate cancer. J Clin Oncol. 2010 Dec 1;28(34):5030-7.
doi: 10.1200/JCO.2010.30.8742. Epub 2010 Nov 1. PMID: 21041708.
17. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone
therapy in men with prostate cancer: a review. Cancer. 2008 Sep
1;113(5):1097-106. doi: 10.1002/cncr.23658. PMID: 18666210; PMCID:
PMC4333639.
18. Thilers PP, Macdonald SW, Herlitz A. The association between
endogenous free testosterone and cognitive performance: a
population-based study in 35 to 90 year-old men and women.
Psychoneuroendocrinology. 2006;31(5):565–76.
19. Jamadar RJ, Winters MJ, Maki PM. Cognitive changes associated with
ADT: A review of the literature. Asian J Androl 2012;14:232-238.
20. Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY,
Park JY, Spiess PE, Fishman MN, Jacobsen PB. Course and Predictors of
Cognitive Function in Patients With Prostate Cancer Receiving
Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol.
2015 Jun 20;33(18):2021-7. doi: 10.1200/JCO.2014.60.1963. Epub 2015 May
11. PMID: 25964245; PMCID: PMC4461804.
21. Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF,
Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA.
Effects of long-term androgen deprivation therapy on cognitive function
over 36 months in men with prostate cancer. Cancer. 2017 Jan
1;123(2):237-244. doi: 10.1002/cncr.30320. Epub 2016 Sep 1. PMID:
27583806.
22. Gandy S, Almeida OP, Fonte J, Lim D, Waterrus A, Spry N, Flicker L,
Martins RN. Chemical andropause and amyloid-beta peptide. JAMA. 2001 May
2;285(17):2195-6. doi: 10.1001/jama.285.17.2195-a. PMID: 11325319.
23. Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer’s
disease. Horm Behav. 2013 Feb;63(2):301-7. doi:
10.1016/j.yhbeh.2012.04.006. Epub 2012 Apr 19. PMID: 22554955; PMCID:
PMC3413783.
24. Tan RS, Pu SJ, Culberson JW. Role of androgens in mild cognitive
impairment and possible interventions during andropause. Med Hypotheses.
2003 Mar;60(3):448-52. doi: 10.1016/s0306-9877(02)00447-4. PMID:
12581627.
25. Beauchet O. Testosterone and cognitive function: current clinical
evidence of a relationship. Eur J Endocrinol. 2006 Dec;155(6):773-81.
doi: 10.1530/eje.1.02306. PMID: 17132744.
26. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C.
Objective and subjective cognitive impairment following chemotherapy for
cancer: a systematic review. Cancer Treat Rev. 2012 Nov;38(7):926-34.
doi: 10.1016/j.ctrv.2012.05.002. Epub 2012 Jun 2. PMID: 22658913.
27. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the ”androgen
deprivation syndrome” in men receiving androgen deprivation for prostate
cancer. Arch Intern Med. 2006 Feb 27;166(4):465-71. doi:
10.1001/archinte.166.4.465. PMID: 16505268; PMCID: PMC2222554.
28. H. J. Green, K. I. Pakenham & R. A. Gardiner (2000) Effects of
luteinizing hormone releasing hormone analogs on cognition in women and
men: A review, Psychology, Health & Medicine, 5:4, 407-418, doi:
10.1080/713690212.
29. Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men
undergoing intermittent combined androgen blockade for non-metastatic
prostate cancer. Psychooncology. 2009 Mar;18(3):237-47. doi:
10.1002/pon.1401. PMID: 18636420; PMCID: PMC2853938.
30. Wu LM, Tanenbaum ML, Dijkers MP, Amidi A, Hall SJ, Penedo FJ,
Diefenbach MA. Cognitive and neurobehavioral symptoms in patients with
non-metastatic prostate cancer treated with androgen deprivation therapy
or observation: A mixed methods study. Soc Sci Med. 2016 May;156:80-9.
doi: 10.1016/j.socscimed.2016.03.016. Epub 2016 Mar 17. PMID: 27019142;
PMCID: PMC4844757.